company background image
GILD34 logo

Gilead Sciences BOVESPA:GILD34 Stock Report

Last Price

R$173.25

Market Cap

R$431.6b

7D

-2.3%

1Y

-18.7%

Updated

23 Apr, 2024

Data

Company Financials +

Gilead Sciences, Inc.

BOVESPA:GILD34 Stock Report

Market Cap: R$431.6b

GILD34 Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD34 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance4/6
Financial Health4/6
Dividends3/6

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$173.25
52 Week HighUS$215.96
52 Week LowUS$164.46
Beta0.20
1 Month Change-5.69%
3 Month Change-10.71%
1 Year Change-18.72%
3 Year Change-2.72%
5 Year Change35.69%
Change since IPO-4.17%

Recent News & Updates

Recent updates

Shareholder Returns

GILD34BR BiotechsBR Market
7D-2.3%-3.0%-1.0%
1Y-18.7%-9.0%13.1%

Return vs Industry: GILD34 underperformed the BR Biotechs industry which returned -9% over the past year.

Return vs Market: GILD34 underperformed the BR Market which returned 13.1% over the past year.

Price Volatility

Is GILD34's price volatile compared to industry and market?
GILD34 volatility
GILD34 Average Weekly Movement2.7%
Biotechs Industry Average Movement9.4%
Market Average Movement4.6%
10% most volatile stocks in BR Market8.7%
10% least volatile stocks in BR Market2.2%

Stable Share Price: GILD34 has not had significant price volatility in the past 3 months.

Volatility Over Time: GILD34's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198718,000Dan O'Daywww.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD34 fundamental statistics
Market capR$431.60b
Earnings (TTM)R$29.29b
Revenue (TTM)R$140.18b

14.7x

P/E Ratio

3.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GILD34 income statement (TTM)
RevenueUS$27.12b
Cost of RevenueUS$6.02b
Gross ProfitUS$21.10b
Other ExpensesUS$15.43b
EarningsUS$5.67b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)4.54
Gross Margin77.80%
Net Profit Margin20.89%
Debt/Equity Ratio109.8%

How did GILD34 perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

66%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.